论文部分内容阅读
每年施行的20,000例角膜移植手术中有10—15％发生移植物排斥。抑制角膜移植物排斥的环孢菌素滴眼剂可能很快将问世。至今为此目的局部应用的环孢菌素尚未制造出来,因为它是脂溶性,并且也不能透过眼房水的基质。但是,路易斯安那州立大学医学中心的Catherine Newton坚信,她已发现一种适宜溶解环孢菌素的物质。但她还不能详细说明它究竟是什么东西。在研究此药的药效学方面,Newton已获得Wellcome公司眼科研究的20,000美元
Graft rejection occurs in 10-15% of 20,000 corneal transplant operations performed each year. Cyclosporine eye drops that inhibit corneal graft rejection may be coming soon. Cyclosporine, which has hitherto been applied for this purpose, has not been produced because it is lipid-soluble and does not transmit through the matrix of aqueous humor either. However, Catherine Newton of the Louisiana State University Medical Center believes she has found a substance that dissolves cyclosporine. But she still can not elaborate on what exactly it is. Newton has received $ 20,000 in Wellcome ophthalmic research to study the pharmacodynamics of this drug